| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Section on Clinical
Pharmacology and 4 Department of
Histochemistry,
To determine a potential role for the renin-angiotensin system in the growth of human pulmonary artery (PA) smooth muscle, we studied the localization of angiotensin (ANG) II-receptor subtypes by autoradiography in sections of human PA and in cultured PA smooth muscle cells (PASMCs) and examined the growth responses to ANG II in vitro. Specific 125I-labeled [Sar1,Ile8]ANG II binding was demonstrated within the pulmonary arterial media, but binding to cultured cells varied between isolates. Binding in tissues and cells was inhibited by the ANG II type 1 (AT1) receptor antagonist losartan but not by the type 2 (AT2) receptor antagonist PD-123319. Microautoradiographic studies indicated that cultured PASMCs exhibit heterogeneity with regard to ANG II binding sites. Addition of ANG II to serum-deprived PASMCs, exhibiting a relatively high level of 125I-[Sar1,Ile8]ANG II binding, led to a dose-dependent stimulation of DNA synthesis at 24 h and protein synthesis at 48 h. ANG II led to an increase in cell size without an increase in cell number. These effects were inhibited by losartan but not by PD-123319. In addition, ANG II led to rapid activation of mitogen-activated protein kinase (MAPK), and ANG II-stimulated DNA synthesis was inhibited by the specific inhibitor of MAPK PD-98059. We conclude that the AT1 receptor is expressed by human PASMCs in vivo and in vitro and is coupled to activation of MAPK and increased DNA and protein synthesis in vitro. These results are consistent with the hypothesis that ANG II may be involved in human pulmonary vascular remodeling.
mitogen-activated protein kinase; vascular remodeling; pulmonary hypertension; angiotensin II type 1 receptors
This article has been cited by other articles:
|
|
 |
|
  B. Rondelet, F. Kerbaul, R. Van Beneden, I. Hubloue, S. Huez, P. Fesler, M. Remmelink, S. Brimioulle, I. Salmon, and R. Naeije Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2319 - H2324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Phillips, L. Long, M. R. Wilkins, and N. W. Morrell cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling Am J Physiol Lung Cell Mol Physiol, January 1, 2005; 288(1): L103 - L115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Aldashev, A. S. Sarybaev, A. S. Sydykov, B. B. Kalmyrzaev, E. V. Kim, L. B. Mamanova, R. Maripov, B. K. Kojonazarov, M. M. Mirrakhimov, M. R. Wilkins, et al. Characterization of High-Altitude Pulmonary Hypertension in the Kyrgyz: Association with Angiotensin-Converting Enzyme Genotype Am. J. Respir. Crit. Care Med., November 15, 2002; 166(10): 1396 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. W. Morrell, X. Yang, P. D. Upton, K. B. Jourdan, N. Morgan, K. K. Sheares, and R. C. Trembath Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-{beta}1 and Bone Morphogenetic Proteins Circulation, August 14, 2001; 104(7): 790 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Upton, J. Wharton, H. Coppock, N. Davie, X. Yang, M. H. Yacoub, M. A. Ghatei, J. M. Polak, S. R. Bloom, D. M. Smith, et al. Adrenomedullin Expression and Growth Inhibitory Effects in Distinct Pulmonary Artery Smooth Muscle Cell Subpopulations Am. J. Respir. Cell Mol. Biol., February 1, 2001; 24(2): 170 - 178. [Abstract] [Full Text]
|
|
|
|
|
|
J. Wharton, N. Davie, P. D. Upton, M. H. Yacoub, J. M. Polak, and N. W. Morrell Prostacyclin Analogues Differentially Inhibit Growth of Distal and Proximal Human Pulmonary Artery Smooth Muscle Cells Circulation, December 19, 2000; 102(25): 3130 - 3136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Gasparo, K. J. Catt, T. Inagami, J. W. Wright, and Th. Unger International Union of Pharmacology. XXIII. The Angiotensin II Receptors Pharmacol. Rev., September 1, 2000; 52(3): 415 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Ortiz, H. C. Champion, J. A. Lasky, F. Gambelli, E. Gozal, G. W. Hoyle, M. B. Beasley, A. L. Hyman, M. Friedman, and P. J. Kadowitz Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappa B and AP-1 Am J Physiol Lung Cell Mol Physiol, June 1, 2002; 282(6): L1209 - L1221. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
